{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:34:47Z","timestamp":1770471287067,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1F30CA284540"],"award-info":[{"award-number":["1F30CA284540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00381-024-06320-z","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:03:13Z","timestamp":1709197393000},"page":"1661-1669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database"],"prefix":"10.1007","volume":"40","author":[{"given":"M. Brandon","family":"Lehrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L. Charles","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. K. Frank","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Edward","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"issue":"2","key":"6320_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.20945\/2359-3997000000600","volume":"67","author":"ML Campanini","year":"2023","unstructured":"Campanini ML, Almeida JP, Martins CS, de Castro M (2023) The molecular pathogenesis of craniopharyngiomas. Arch Endocrinol Metab 67(2):266\u2013275. https:\/\/doi.org\/10.20945\/2359-3997000000600","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"6320_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11102-021-01127-6","volume":"24","author":"AA Momin","year":"2021","unstructured":"Momin AA, Recinos MA, Cioffi G et al (2021) Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary 24(4):517\u2013522. https:\/\/doi.org\/10.1007\/s11102-021-01127-6","journal-title":"Pituitary"},{"issue":"1","key":"6320_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/s-0037-1621738","volume":"79","author":"CS Graffeo","year":"2018","unstructured":"Graffeo CS, Perry A, Link MJ, Daniels DJ (2018) Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. J Neurol Surg B Skull Base 79(1):65\u201380. https:\/\/doi.org\/10.1055\/s-0037-1621738","journal-title":"J Neurol Surg B Skull Base"},{"key":"6320_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105711","volume":"192","author":"S Sadashivam","year":"2020","unstructured":"Sadashivam S, Menon G, Abraham M, Nair SN (2020) Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome. Clin Neurol Neurosurg 192:105711. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105711","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"6320_CR5","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2010.1.FOCUS09307","volume":"28","author":"I Yang","year":"2010","unstructured":"Yang I, Sughrue ME, Rutkowski MJ et al (2010) Craniopharyngioma: A comparison of tumor control with various treatment strategies. Neurosurg Focus 28(4):E5. https:\/\/doi.org\/10.3171\/2010.1.FOCUS09307","journal-title":"Neurosurg Focus"},{"issue":"5","key":"6320_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00381-021-05094-y","volume":"37","author":"BM Lehrich","year":"2021","unstructured":"Lehrich BM, Goshtasbi K, Hsu FPK, Kuan EC (2021) Characteristics and overall survival in pediatric versus adult craniopharyngioma: A population-based study. Childs Nerv Syst 37(5):1535\u20131545. https:\/\/doi.org\/10.1007\/s00381-021-05094-y","journal-title":"Childs Nerv Syst"},{"key":"6320_CR7","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/j.wneu.2022.08.068","volume":"167","author":"A Abiri","year":"2022","unstructured":"Abiri A, Roman KM, Latif K et al (2022) Endoscopic versus Nonendoscopic Surgery for Resection of Craniopharyngiomas. World Neurosurg 167:e629\u2013e638. https:\/\/doi.org\/10.1016\/j.wneu.2022.08.068","journal-title":"World Neurosurg"},{"key":"6320_CR8","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.wneu.2019.08.209","volume":"133","author":"HJ Park","year":"2020","unstructured":"Park HJ, Dho YS, Kim JH, Kim JW, Park CK, Kim YH (2020) Recurrence rate and prognostic factors for the adult craniopharyngiomas in long-term follow-up. World Neurosurg 133:e211\u2013e217. https:\/\/doi.org\/10.1016\/j.wneu.2019.08.209","journal-title":"World Neurosurg"},{"issue":"5","key":"6320_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3171\/2021.5.JNS202011","volume":"136","author":"SS Godil","year":"2022","unstructured":"Godil SS, Tosi U, Gerges M et al (2022) Long-term tumor control after endoscopic endonasal resection of craniopharyngiomas: Comparison of gross-total resection versus subtotal resection with radiation therapy. J Neurosurg 136(5):1347\u20131355. https:\/\/doi.org\/10.3171\/2021.5.JNS202011","journal-title":"J Neurosurg"},{"issue":"10","key":"6320_CR10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.radcr.2020.07.015","volume":"15","author":"L Burgess","year":"2020","unstructured":"Burgess L, Chakraborty S, Malone S (2020) Effective salvage of recurrent craniopharyngioma with fractionated stereotactic radiotherapy. Radiol Case Rep 15(10):1750\u20131755. https:\/\/doi.org\/10.1016\/j.radcr.2020.07.015","journal-title":"Radiol Case Rep"},{"issue":"2","key":"6320_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.17925\/EE.2021.17.2.121","volume":"17","author":"KI Alexandraki","year":"2021","unstructured":"Alexandraki KI, Xekouki P (2021) Medical therapy for craniopharyngiomas. touchREV Endocrinol 17(2):121\u2013132. https:\/\/doi.org\/10.17925\/EE.2021.17.2.121","journal-title":"touchREV Endocrinol"},{"issue":"2","key":"6320_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE et al (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46(2):161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet"},{"issue":"8","key":"6320_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"Consortium APG","year":"2017","unstructured":"Consortium APG (2017) AACR project GENIE: Powering precision medicine through an international consortium. Cancer Discov 7(8):818\u2013831. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0151","journal-title":"Cancer Discov"},{"key":"6320_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23267","author":"BM Lehrich","year":"2023","unstructured":"Lehrich BM, Abiri A, Nguyen TV, Bitner BF, Tong CCL, Kuan EC (2023) Mutational landscape and predictors of survival in head and neck mucosal melanoma. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.23267","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"6320_CR15","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/s0002-9440(10)64477-x","volume":"161","author":"S Sekine","year":"2002","unstructured":"Sekine S, Shibata T, Kokubu A et al (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161(6):1997\u20132001. https:\/\/doi.org\/10.1016\/s0002-9440(10)64477-x","journal-title":"Am J Pathol"},{"issue":"3","key":"6320_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-017-2465-1","volume":"133","author":"PB Malgulwar","year":"2017","unstructured":"Malgulwar PB, Nambirajan A, Pathak P et al (2017) Study of beta-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: Mutation analysis with immunohistochemical correlation in 54 cases. J Neurooncol 133(3):487\u2013495. https:\/\/doi.org\/10.1007\/s11060-017-2465-1","journal-title":"J Neurooncol"},{"issue":"6","key":"6320_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1227\/neu.0000000000002346","volume":"92","author":"JC Pang","year":"2023","unstructured":"Pang JC, Chung DD, Wang J et al (2023) Characteristics and outcomes in pediatric versus adult craniopharyngiomas: A systematic review and meta-analysis. Neurosurgery 92(6):1112\u20131129. https:\/\/doi.org\/10.1227\/neu.0000000000002346","journal-title":"Neurosurgery"},{"issue":"1","key":"6320_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-020-00939-0","volume":"8","author":"E Prince","year":"2020","unstructured":"Prince E, Whelan R, Donson A et al (2020) Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets. Acta Neuropathol Commun 8(1):68. https:\/\/doi.org\/10.1186\/s40478-020-00939-0","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"6320_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM et al (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol 135(5):757\u2013777. https:\/\/doi.org\/10.1007\/s00401-018-1830-2","journal-title":"Acta Neuropathol"},{"issue":"2","key":"6320_CR20","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2016","unstructured":"Brastianos PK, Shankar GM, Gill CM et al (2016) Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 108(2):djv310. https:\/\/doi.org\/10.1093\/jnci\/djv310","journal-title":"J Natl Cancer Inst"},{"key":"6320_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F, Jacquesson T, Manet R et al (2022) Neoadjuvant B-RAF and MEK Inhibitor targeted therapy for adult papillary craniopharyngiomas: A new treatment paradigm. Front Endocrinol (Lausanne) 13:882381. https:\/\/doi.org\/10.3389\/fendo.2022.882381","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6320_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S et al (2023) BRAF-MEK Inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 389(2):118\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2213329","journal-title":"N Engl J Med"},{"issue":"3","key":"6320_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11102-022-01212-4","volume":"25","author":"P Iglesias","year":"2022","unstructured":"Iglesias P (2022) Targeted therapies in the medical management of craniopharyngioma. Pituitary 25(3):383\u2013392. https:\/\/doi.org\/10.1007\/s11102-022-01212-4","journal-title":"Pituitary"},{"issue":"17","key":"6320_CR24","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Jones PS, Wang N et al (2019) Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125(17):2910\u20132914. https:\/\/doi.org\/10.1002\/cncr.32197","journal-title":"Cancer"},{"issue":"1","key":"6320_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14348\/molcells.2018.0436","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim S, Jeong S (2019) Mutation hotspots in the beta-catenin gene: Lessons from the human cancer genome databases. Mol Cells 42(1):8\u201316. https:\/\/doi.org\/10.14348\/molcells.2018.0436","journal-title":"Mol Cells"},{"issue":"3","key":"6320_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","volume":"147","author":"J Tao","year":"2014","unstructured":"Tao J, Calvisi DF, Ranganathan S et al (2014) Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147(3):690\u2013701. https:\/\/doi.org\/10.1053\/j.gastro.2014.05.004","journal-title":"Gastroenterology"},{"issue":"4","key":"6320_CR27","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.18632\/oncotarget.23695","volume":"9","author":"C Gao","year":"2018","unstructured":"Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: A review. Oncotarget 9(4):5492\u20135508. https:\/\/doi.org\/10.18632\/oncotarget.23695","journal-title":"Oncotarget"},{"issue":"8","key":"6320_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.tibs.2018.06.003","volume":"43","author":"C Cui","year":"2018","unstructured":"Cui C, Zhou X, Zhang W, Qu Y, Ke X (2018) Is beta-catenin a druggable target for cancer therapy? Trends Biochem Sci 43(8):623\u2013634. https:\/\/doi.org\/10.1016\/j.tibs.2018.06.003","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"6320_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jhep.2021.01.044","volume":"75","author":"B Liang","year":"2021","unstructured":"Liang B, Zhou Y, Qian M et al (2021) TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. J Hepatol 75(1):120\u2013131. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.044","journal-title":"J Hepatol"},{"issue":"24","key":"6320_CR30","doi-asserted-by":"publisher","first-page":"e161408","DOI":"10.1172\/JCI161408","volume":"132","author":"W Dai","year":"2022","unstructured":"Dai W, Shen J, Yan J et al (2022) Glutamine synthetase limits beta-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1. J Clin Invest 132(24):e161408. https:\/\/doi.org\/10.1172\/JCI161408","journal-title":"J Clin Invest"},{"issue":"9","key":"6320_CR31","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1158\/1535-7163.MCT-16-0309","volume":"15","author":"S Ganesh","year":"2016","unstructured":"Ganesh S, Koser ML, Cyr WA et al (2016) Direct pharmacological inhibition of beta-catenin by RNA interference in tumors of diverse origin. Mol Cancer Ther 15(9):2143\u20132154. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0309","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"6320_CR32","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.28638","volume":"64","author":"S Rebouissou","year":"2016","unstructured":"Rebouissou S, Franconi A, Calderaro J et al (2016) Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology 64(6):2047\u20132061. https:\/\/doi.org\/10.1002\/hep.28638","journal-title":"Hepatology"},{"issue":"4","key":"6320_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/bpa.12525","volume":"28","author":"JKR Boult","year":"2018","unstructured":"Boult JKR, Apps JR, Holsken A et al (2018) Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. Brain Pathol 28(4):475\u2013483. https:\/\/doi.org\/10.1111\/bpa.12525","journal-title":"Brain Pathol"},{"issue":"3","key":"6320_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bpa.12501","volume":"27","author":"JR Apps","year":"2017","unstructured":"Apps JR, Martinez-Barbera JP (2017) Genetically engineered mouse models of craniopharyngioma: An opportunity for therapy development and understanding of tumor biology. Brain Pathol 27(3):364\u2013369. https:\/\/doi.org\/10.1111\/bpa.12501","journal-title":"Brain Pathol"},{"issue":"28","key":"6320_CR35","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.1073\/pnas.1101553108","volume":"108","author":"C Gaston-Massuet","year":"2011","unstructured":"Gaston-Massuet C, Andoniadou CL, Signore M et al (2011) Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans. Proc Natl Acad Sci USA 108(28):11482\u201311487. https:\/\/doi.org\/10.1073\/pnas.1101553108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6320_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-017-0562-9","volume":"36","author":"E Guadagno","year":"2017","unstructured":"Guadagno E, de Divitiis O, Solari D et al (2017) Can recurrences be predicted in craniopharyngiomas? beta-catenin coexisting with stem cells markers and p-ATM in a clinicopathologic study of 45cases. J Exp Clin Cancer Res 36(1):95. https:\/\/doi.org\/10.1186\/s13046-017-0562-9","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"6320_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","volume":"31","author":"G Kim","year":"2018","unstructured":"Kim G, Kurnit KC, Djordjevic B et al (2018) Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31(10):1553\u20131559. https:\/\/doi.org\/10.1038\/s41379-018-0080-0","journal-title":"Mod Pathol"},{"issue":"5","key":"6320_CR38","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.21037\/jtd.2020.03.78","volume":"12","author":"B Gini","year":"2020","unstructured":"Gini B, Thomas N, Blakely CM (2020) Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis 12(5):2883\u20132895. https:\/\/doi.org\/10.21037\/jtd.2020.03.78","journal-title":"J Thorac Dis"},{"issue":"5","key":"6320_CR39","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/hep.28975","volume":"65","author":"J Tao","year":"2017","unstructured":"Tao J, Zhang R, Singh S et al (2017) Targeting beta-catenin in hepatocellular cancers induced by coexpression of mutant beta-catenin and K-Ras in mice. Hepatology 65(5):1581\u20131599. https:\/\/doi.org\/10.1002\/hep.28975","journal-title":"Hepatology"},{"issue":"5","key":"6320_CR40","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/hep.28601","volume":"64","author":"J Tao","year":"2016","unstructured":"Tao J, Xu E, Zhao Y et al (2016) Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant beta-catenin. Hepatology 64(5):1587\u20131605. https:\/\/doi.org\/10.1002\/hep.28601","journal-title":"Hepatology"},{"issue":"2","key":"6320_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/hep.31730","volume":"74","author":"J Tao","year":"2021","unstructured":"Tao J, Krutsenko Y, Moghe A et al (2021) Nuclear factor erythroid 2-related factor 2 and beta-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology 74(2):741\u2013759. https:\/\/doi.org\/10.1002\/hep.31730","journal-title":"Hepatology"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06320-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-024-06320-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06320-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T10:04:23Z","timestamp":1716372263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-024-06320-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6320"],"URL":"https:\/\/doi.org\/10.1007\/s00381-024-06320-z","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"7 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}